Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
The efficacy and safety of avelumab maintenance therapy was not significantly influenced by age, PS, or infusion timing, and PFS ≥6 months could be a surrogate marker for OS.
Authors
- Manabu Mochida
- Takahito Negishi (ORCID: https://orcid.org/0000-0002-6645-8829)
- Aki Kijima
- Nobuki Furubayashi (ORCID: https://orcid.org/0000-0001-9159-493X)
- Motonobu Nakamura (ORCID: https://orcid.org/0000-0003-3038-1361)
- Yo Fujimoto
Institutions
- National Hospital Organization Kyushu Cancer Center (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13903
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00